- Home
- BCYC
as of 03-13-2026 1:24pm EST
$4.87
$0.17
-3.47%
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
| Founded: | 2009 | Country: | United Kingdom |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 360.7M | IPO Year: | 2019 |
| Target Price: | $17.56 | AVG Volume (30 days): | 333.2K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | quarterly |
| EPS: | -2.87 | EPS Growth: | 42.91 |
| 52 Week Low/High: | $5.00 - $10.13 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -6.3% | Revenue Growth (next year): | -5.74% |
| P/E Ratio: | -1.76 | Index: | N/A |
| Free Cash Flow: | -165959000.0 | FCF Growth: | N/A |
AI-Powered BCYC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 18 hours ago
AI Recommendation
hold
Model Accuracy: 71.88%
71.88%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Bicycle Therapeutics plc (BCYC)
Skynner Michael
Sell
CHIEF TECHNOLOGY OFFICER
BCYC Jan 5, 2026
Avg Cost/Share
$6.46
Shares
3,266
Total Value
$21,098.36
Owned After
161,966
SEC Form 4
Hannay Michael Charles Ferguson
Sell
CHIEF PROD & SUPPLY CHAIN OFF
BCYC Jan 5, 2026
Avg Cost/Share
$6.45
Shares
2,367
Total Value
$15,267.15
Owned After
97,908
SEC Form 4
Thompson Travis Alvin
Sell
CHIEF ACCOUNTING OFFICER
BCYC Jan 5, 2026
Avg Cost/Share
$6.45
Shares
1,115
Total Value
$7,191.75
Owned After
66,265
SEC Form 4
Young Alethia
Sell
Chief Financial Officer
BCYC Jan 5, 2026
Avg Cost/Share
$6.50
Shares
4,334
Total Value
$28,123.32
Owned After
88,959
Milnes Alistair
Sell
CHIEF OPERATING OFFICER
BCYC Jan 5, 2026
Avg Cost/Share
$6.46
Shares
3,416
Total Value
$22,067.36
Owned After
136,717
SEC Form 4
Skynner Michael
Sell
CHIEF TECHNOLOGY OFFICER
BCYC Jan 2, 2026
Avg Cost/Share
$6.80
Shares
3,045
Total Value
$20,706.00
Owned After
161,966
SEC Form 4
Hannay Michael Charles Ferguson
Sell
CHIEF PROD & SUPPLY CHAIN OFF
BCYC Jan 2, 2026
Avg Cost/Share
$6.80
Shares
2,827
Total Value
$19,223.60
Owned After
97,908
SEC Form 4
Thompson Travis Alvin
Sell
CHIEF ACCOUNTING OFFICER
BCYC Jan 2, 2026
Avg Cost/Share
$6.80
Shares
1,317
Total Value
$8,955.60
Owned After
66,265
SEC Form 4
Young Alethia
Sell
Chief Financial Officer
BCYC Jan 2, 2026
Avg Cost/Share
$6.80
Shares
3,289
Total Value
$22,365.20
Owned After
88,959
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Jan 5, 2026 | Sell | $6.46 | 3,266 | $21,098.36 | 161,966 | |
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Jan 5, 2026 | Sell | $6.45 | 2,367 | $15,267.15 | 97,908 | |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Jan 5, 2026 | Sell | $6.45 | 1,115 | $7,191.75 | 66,265 | |
| Young Alethia | BCYC | Chief Financial Officer | Jan 5, 2026 | Sell | $6.50 | 4,334 | $28,123.32 | 88,959 | |
| Milnes Alistair | BCYC | CHIEF OPERATING OFFICER | Jan 5, 2026 | Sell | $6.46 | 3,416 | $22,067.36 | 136,717 | |
| Lee Kevin | BCYC | CHIEF EXECUTIVE OFFICER | Jan 5, 2026 | Sell | $6.46 | 10,989 | $70,988.94 | 618,996 | |
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Jan 2, 2026 | Sell | $6.80 | 3,045 | $20,706.00 | 161,966 | |
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Jan 2, 2026 | Sell | $6.80 | 2,827 | $19,223.60 | 97,908 | |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Jan 2, 2026 | Sell | $6.80 | 1,317 | $8,955.60 | 66,265 | |
| Young Alethia | BCYC | Chief Financial Officer | Jan 2, 2026 | Sell | $6.80 | 3,289 | $22,365.20 | 88,959 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Oct 30, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLOct 30, 2025 · 100% conf.
AI Prediction SELL
1D
+0.27%
$8.78
Act: -7.88%
5D
-5.71%
$8.26
Act: -25.68%
20D
-9.05%
$7.97
Act: -14.73%
Price: $8.76 Prob +5D: 0% AUC: 1.000
0001104659-25-104004
false 0001761612 X0 00-0000000 true
0001761612
2025-10-30 2025-10-30
0001761612
us-gaap:CommonStockMember
2025-10-30 2025-10-30
0001761612
bcyc:AmericanDepositarySharesMember
2025-10-30 2025-10-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 30, 2025
Date of Report (Date of earliest event reported)
Bicycle Therapeutics plc
(Exact name of registrant as specified in its charter)
England and Wales
001-38916
Not applicable
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
Blocks A & B, Portway Building, Granta Park Great Abington, Cambridge
United Kingdom
CB21
6GS
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: +44 1223 261503
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol (s) Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
BCYC
The Nasdaq Stock Market LLC
* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition
On October 30, 2025, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended September 30, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press Release issued October 30, 2025
104
Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 30, 2025
BICYCLE THERAPEUTICS
PLC
By: /s/ Alethia Young
Name: Alethia Young
Title: Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 8, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 8, 2025
0001104659-25-075435
false 0001761612 X0 00-0000000 true
0001761612
2025-08-06 2025-08-06
0001761612
us-gaap:CommonStockMember
2025-08-06 2025-08-06
0001761612
bcyc:AmericanDepositarySharesMember
2025-08-06 2025-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 6, 2025
Date of Report (Date of earliest event reported)
Bicycle Therapeutics plc
(Exact name of registrant as specified in its charter)
England and Wales
001-38916
Not applicable
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
Blocks A & B, Portway Building, Granta Park Great Abington, Cambridge
United Kingdom
CB21
6GS
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: +44 1223 261503
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol (s) Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
BCYC
The Nasdaq Stock Market LLC
* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition
On August 8, 2025, Bicycle Therapeutics plc (the “Company”) issued a press release announcing financial results for the fiscal quarter ended June 30, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 6, 2025, the Company’s Board of Directors (the “Board”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP, to the Board and the Scientific Committee of the Board, effective as of August 12, 2025, New York City time. The Board has determined that Dr. Swanton is not an “independent” director pursuant to the rules of the Nasdaq Stock Market LLC and other governing laws and applicable regulations due to his service to the Company as Chair of the Clinical Advisory Board. Dr. Swanton will serve as a Class II director until the Company’s 2027 annual general meeting, and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
There are no arrangements or understandings between Dr. Swanton and any other person pursuant to which Dr. Swanton was appointed as a director. Dr. Swanton does not have any family relationships with any of the Company’s directors or executive officers, and he does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
As a non-employee director of the Company, Dr. Swanton will participate
in the Company’s Non-Employee Director Compensation Policy, as amended (the “Policy). Pursuant to the Policy, Dr. Swanton will receive (i) annual cash compensation of $50,000 for his service as a dir
2025 Q1 Q1 2025 Earnings
8-K May 1, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 1, 2025
0001104659-25-043014
false 0001761612 X0 00-0000000 true
0001761612
2025-05-01 2025-05-01
0001761612
us-gaap:CommonStockMember
2025-05-01 2025-05-01
0001761612
bcyc:AmericanDepositarySharesMember
2025-05-01 2025-05-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 1, 2025
Date of Report (Date of earliest event reported)
Bicycle Therapeutics plc
(Exact name of registrant as specified in its charter)
England and Wales
001-38916
Not applicable
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
Blocks A & B, Portway Building, Granta Park Great Abington, Cambridge
United Kingdom
CB21
6GS
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: +44 1223 261503
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading
Symbol (s) Name of each exchange on which
registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
BCYC
The Nasdaq Stock Market LLC
* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition
On May 1, 2025, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended March 31, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press Release issued May 1, 2025
104
Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 1, 2025
BICYCLE THERAPEUTICS PLC
By: /s/ Alethia Young
Name: Alethia Young
Title: Chief Financial Officer
Latest Bicycle Therapeutics plc News
BCYC Breaking Stock News: Dive into BCYC Ticker-Specific Updates for Smart Investing
Compare BCYC vs Leading Stocks
See how BCYC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BCYC Bicycle Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.